Dr. RAJENDRA SANGARAJU

About

I am Dr. Sangaraju Rajendra, working as Research Scientist in the Department of Biological Sciences (Regulatory Toxicology) at the National Institute of Pharmaceutical Education and Research-Hyderabad. I have completed my Post-Doctoral Research work as an ICMR-Research Associate at the Indian Council of Medical Research- National Institute of Nutrition. I have completed my Ph.D. degree in biological sciences at CSIR-Indian Institute of Chemical Technology and was awarded by the university as Academy of Scientific and Innovative Research, New Delhi, India.

I am a Pharmacology and Translational Biomedical Research Scientist with extensive experience in preclinical drug discovery, disease modeling, and mechanism-driven therapeutic validation. My work integrates in-vitro, in-vivo, and molecular approaches to advance translational research across inflammation, psoriasis, fibrosis (lung and liver), NASH/MASLD, neonatal sepsis, cancer, metabolic disorders, and stem cell biology.

I currently work in translational pharmacology research at NIPER, with prior research appointments at ICMR–National Institute of Nutrition and CSIR–IICT. I have contributed to multiple national and grant-funded research programs under CSIR as a Junior Research Fellow, Senior Research Fellow, and ICMR as a Research Associate. My research focuses on experimental pharmacology, compound screening, pathway and target validation, and development of translational disease models.

I have authored multiple peer-reviewed international publications & Book chapters and am a co-inventor on a multi-jurisdiction international patent family covering anti-inflammatory therapeutic compounds for dermal disorders across the US, Europe, Japan, China, Australia, Canada, Taiwan, and Hong Kong, WIPO (PCT). My research contributions emphasize mechanism-based pharmacology, therapeutic profiling, and evidence-driven validation strategies.

I was selected for the ARCH Australia–India Research Student Fellowship at RMIT University, Melbourne, supporting international collaborative research between Indian and Australian institutes and strengthening my global research engagement.

My broader research interests include inflammation biology, fibrosis, metabolic disease, pesticide toxicology, and phytochemical-based therapeutics. I work extensively on molecular signaling pathways, oxidative stress biology, and natural product pharmacology to develop translationally relevant therapeutic strategies.

Core expertise includes: Preclinical disease models • In-vitro & In-vivo pharmacology • Drug discovery & screening • Fibrosis and inflammatory disorders • Neonatal sepsis • Psoriasis & ulcerative colitis • Arthritis • Cancer biology • Wound healing • Metabolic disease research • Cell culture & biological assays • Molecular biology techniques • Mechanistic pathway analysis • Grant research execution • Scientific writing & reviewing • Data analysis and interpretation • Publications & patents.

Actively engaged in multi-center, grant-driven translational research programs focused on preclinical pharmacology and therapeutic development.

Employment

• National Institute of Pharmaceutical Education and Research Research Scientist
  2024 - Present
• National Institute of Nutrition Indian Council of Medical Research- Research Associate
  2022 - 2024

Education

• Academy of Scientific and Innovative Research Ph.D. Biological Sciences/ Pharmacology
  2016 - 2021

Projects & Funding

Projects & funding information is unavailable.

Publications (17)

• Stevioside alleviates high-fat diet-induced MASLD in Apo-E‑/‑ mice by modulating the TGF-β signaling
  The Journal of Nutritional Biochemistry 2025 DOI: 10.1016/j.jnutbio.2025.110125
  +Save
• Effect of ethyl acetate extract of the whole plant Clerodendrum phlomidis on improving bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) in Rats: In vitro and in vivo research
  International Immunopharmacology 2025 DOI: 10.1016/j.intimp.2024.113688
  +Save
• Modulation of inflammatory and cuproptotic crosstalk by Ethyl and propyl gallate: a multi-targeted strategy against experimental colitis
  Molecular Biology Reports 2025 DOI: 10.1007/s11033-025-11098-7
  +Save
• Extraction, Phytochemical profile, and neuroprotective activity of Phyllanthus emblica fruit extract against sodium valproate-induced postnatal autism in BALB/c mice
  Heliyon 2024 DOI: 10.1016/j.heliyon.2024.e34992
  +Save
• Assessing farmer's exposure to pesticides and the risk for non-communicable diseases: A biomonitoring study
  Science of The Total Environment 2023 DOI: 10.1016/j.scitotenv.2023.164429
  +Save
• Effect of ethyl gallate and propyl gallate on dextran sulfate sodium (DSS)-induced ulcerative colitis in C57BL/6 J mice: preventive and protective
  Inflammopharmacology 2023 DOI: 10.1007/s10787-023-01254-5
  +Save
• Investigation of acute organophosphate poisoning in humans based on sociodemographic and role of neurotransmitters with survival study in South India
  Scientific Reports 2022 DOI: 10.1038/s41598-022-21054-1
  +Save
• Identification and characterization of Ethyl gallate from Ethyl acetate fraction of Phyllanthus emblica fruit, and invitro free radical scavenging activity
  International journal of health sciences 2022 DOI: 10.53730/ijhs.v6ns8.12333
  +Save
• A novel RP-HPLC method for quantification of cholinesterase activity in human blood: An application for assessing organophosphate and carbamate insecticide exposure
  PLOS ONE 2022 DOI: 10.1371/journal.pone.0279287
  +Save
• Galangin ameliorates Imiquimod-Induced psoriasis-like skin inflammation in BALB/c mice via down regulating NF-κB and activation of Nrf2 signaling pathways
  International Immunopharmacology 2021 DOI: 10.1016/j.intimp.2021.107754
  +Save